资金流向方面，主力资金净流出71.64万元，特大单买入111.61万元，占比3.07%，卖出0.00元，占比 0.00%；大单买入281.84万元，占比7.76%，卖出465.09万元，占比12.80%。 11月14日，沃华医药（维权）盘中上涨2.16%，截至10:15，报6.62元/股，成交3633.69万元，换手率 0.97%，总市值38.21亿元。 截至9月30日，沃华医药股东户数4.10万，较上期增加17.18%；人均流通股13892股，较上期减少 14.66%。2025年1月-9月，沃华医药实现营业收入6.25亿元，同比增长8.31%；归母净利润6399.50万元， 同比增长179.34%。 分红方面，沃华医药A股上市后累计派现6.92亿元。近三年，累计派现2.14亿元。 机构持仓方面，截止2025年9月30日，沃华医药十大流通股东中，博道久航混合A（008318）位居第八 大流通股东，持股99.89万股，为新进股东。国泰海通中证500指数增强A（014155）位居第十大流通股 东，持股93.12万股，为新进股东。博道远航混合A（007126）退出十大流通股东之列。 责任编辑：小浪快报 沃华医药今年 ...

Core Insights - Wohuah Pharmaceutical's stock price increased by 2.13% on October 31, reaching 6.22 CNY per share, with a total market capitalization of 3.59 billion CNY [1] - The company has seen a year-to-date stock price increase of 33.48%, but has experienced a slight decline of 0.32% over the last five trading days [1] Financial Performance - For the period from January to September 2025, Wohuah Pharmaceutical reported a revenue of 625 million CNY, representing a year-on-year growth of 8.31% [2] - The net profit attributable to shareholders for the same period was 63.995 million CNY, showing a significant year-on-year increase of 179.34% [2] Shareholder Information - As of September 30, 2025, the number of shareholders increased to 41,000, up by 17.18% from the previous period [2] - The average number of circulating shares per shareholder decreased by 14.66% to 13,892 shares [2] Dividend Distribution - Since its A-share listing, Wohuah Pharmaceutical has distributed a total of 692 million CNY in dividends, with 214 million CNY distributed over the last three years [3] Institutional Holdings - As of September 30, 2025, notable new institutional shareholders include Baodao Jiuhang Mixed A and Guotai Haitong CSI 500 Index Enhanced A, holding 998,900 shares and 931,200 shares respectively [3]